Upon treatment with TGFβ1, organoids adopted a transcriptional profile highly similar to the transcriptome of CMS4 cancers which are characterized by TGFβ pathway activation, mesenchymal features, high stromal content, and particularly poor prognosis [30]. This evidence concerns the gene TGFB1 and cancer.